» Articles » PMID: 37695742

Comprehensive Analysis of ICD-related LncRNAs in Predicting Risk Stratification, Clinical Prognosis and Immune Response for Breast Cancer

Overview
Specialty Geriatrics
Date 2023 Sep 11
PMID 37695742
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Breast cancer (BRCA) represents a significant threat with high mortality rates due to relapse, metastasis, and chemotherapy resistance. As a regulated cell death process characterized by the induction of immunogenic signals, immunogenic cell death (ICD) has been identified as an effective anti-tumorigenesis approach. However, the comprehensive study and its clinical value of ICD-related lncRNAs in BRCA is still missing.

Methods: The transcriptome matrix and corresponding clinical information of BRCA patients were obtained from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was performed to identify ICD-related lncRNAs (ICDRLs). To determine the prognostic value of the identified ICDRLs, univariate Cox regression analysis, LASSO algorithm, and multivariate Cox regression analysis were employed to construct a risk model. The prognostic risk model was subsequently evaluated using univariate and multivariate Cox regression analysis, as well as Nomogram analysis. experiments were also conducted to validate the bioinformatics findings using quantitative real-time PCR (qRT-PCR).

Results: We established a prognostic risk signature consisting of five ICDRLs. The prognostic value of this model was subsequently confirmed in guiding BRCA prognostic stratification. Furthermore, we explored the correlation of the risk score with various clinical characteristics and chemotherapy response. qRT-PCR result confirmed the abnormal expression of ICDRLs, which was consistent with the bioinformatics data.

Conclusions: Our findings provide evidence of the critical role of ICDRLs in BRCA and offer a novel perspective for exploring precise treatment options for BRCA patients.

Citing Articles

A new paradigm for cancer immunotherapy: targeting immunogenic cell death-related noncoding RNA.

Sun G, He L Front Immunol. 2025; 15:1498781.

PMID: 39916954 PMC: 11798941. DOI: 10.3389/fimmu.2024.1498781.


Addressing the Gap: Racial Disparities and Public Health Strategies in the Epidemiology of Gastrointestinal Stromal Tumors.

Rammohan R, Joy M, Magam S, Lau W, Natt D, Tadikonda A Cureus. 2024; 16(6):e61743.

PMID: 38975445 PMC: 11226192. DOI: 10.7759/cureus.61743.

References
1.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Buque Martinez A . Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020; 8(1). PMC: 7064135. DOI: 10.1136/jitc-2019-000337. View

2.
Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32(27):2959-66. PMC: 4162494. DOI: 10.1200/JCO.2013.55.0491. View

3.
Tao S, Tao K, Cai X . Necroptosis-Associated lncRNA Prognostic Model and Clustering Analysis: Prognosis Prediction and Tumor-Infiltrating Lymphocytes in Breast Cancer. J Oncol. 2022; 2022:7099930. PMC: 9068297. DOI: 10.1155/2022/7099930. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
Qiu X, Qu Y, Guo B, Zheng H, Meng F, Zhong Z . Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer. J Control Release. 2021; 341:498-510. DOI: 10.1016/j.jconrel.2021.12.002. View